PubMed:25420889 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":495,"end":509},"obj":"HP_0002592"}],"text":"The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study.\nOBJECTIVE: Ecabet sodium (ES) is a new non-systemic anti-ulcer agent belonging to the category of gastroprotective agents. In this study we aimed to compare the efficacy of a combination therapy with lansoprazole (LS) followed by ES with LS alone in treating endoscopic submucosal dissection (ESD)-induced iatrogenic gastric ulcers.\nMETHODS: Patients diagnosed with gastric adenomas or early gastric cancer were randomly divided into either the LS group (30 mg once daily for 4 weeks; n = 45) or the LS + ES group (LS 30 mg once daily for one week followed by ES 1500 mg twice daily for 3 weeks; n = 45). Four weeks after ESD, a follow-up endoscopy was conducted to evaluate the proportions of ulcer reduction and ulcer stages in the two groups.\nRESULTS: In all, 79 patients were included in the final analyses. Both treatment modalities were well-tolerated in most patients, with a drug compliance of over 80%. There were no significant differences between the two groups in terms of the proportions of ulcer reduction (0.9503 ± 0.1215 in the LS group vs 0.9192 ± 0.0700 in the LS + ES group, P = 0.169) or ulcer stage (P = 0.446). The prevalence of adverse events related to drugs and bleeding were also similar between the two groups.\nCONCLUSION: Sequential therapy with LS + ES is as effective as LS alone against ESD-induced gastric ulcers."}

{"project":"Zierdiyeerkenaili_800_3","denotations":[{"id":"T1","span":{"begin":204,"end":206},"obj":"CI"},{"id":"T10","span":{"begin":1222,"end":1224},"obj":"CI"},{"id":"T11","span":{"begin":1479,"end":1481},"obj":"CI"},{"id":"T12","span":{"begin":55,"end":68},"obj":"CI"},{"id":"T13","span":{"begin":544,"end":560},"obj":"DP"},{"id":"T14","span":{"begin":564,"end":584},"obj":"DP"},{"id":"T2","span":{"begin":408,"end":410},"obj":"CI"},{"id":"T3","span":{"begin":189,"end":202},"obj":"CI"},{"id":"T4","span":{"begin":378,"end":390},"obj":"CI"},{"id":"T5","span":{"begin":38,"end":50},"obj":"CI"},{"id":"T6","span":{"begin":392,"end":394},"obj":"CI"},{"id":"T7","span":{"begin":416,"end":418},"obj":"CI"},{"id":"T8","span":{"begin":623,"end":625},"obj":"CI"},{"id":"T9","span":{"begin":693,"end":695},"obj":"CI"},{"id":"T15","span":{"begin":678,"end":681},"obj":"CI"},{"id":"T16","span":{"begin":1257,"end":1260},"obj":"CI"},{"id":"T17","span":{"begin":1452,"end":1455},"obj":"CI"},{"id":"T18","span":{"begin":682,"end":685},"obj":"CI"},{"id":"T19","span":{"begin":1261,"end":1264},"obj":"CI"},{"id":"T20","span":{"begin":1456,"end":1459},"obj":"CI"}],"text":"The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study.\nOBJECTIVE: Ecabet sodium (ES) is a new non-systemic anti-ulcer agent belonging to the category of gastroprotective agents. In this study we aimed to compare the efficacy of a combination therapy with lansoprazole (LS) followed by ES with LS alone in treating endoscopic submucosal dissection (ESD)-induced iatrogenic gastric ulcers.\nMETHODS: Patients diagnosed with gastric adenomas or early gastric cancer were randomly divided into either the LS group (30 mg once daily for 4 weeks; n = 45) or the LS + ES group (LS 30 mg once daily for one week followed by ES 1500 mg twice daily for 3 weeks; n = 45). Four weeks after ESD, a follow-up endoscopy was conducted to evaluate the proportions of ulcer reduction and ulcer stages in the two groups.\nRESULTS: In all, 79 patients were included in the final analyses. Both treatment modalities were well-tolerated in most patients, with a drug compliance of over 80%. There were no significant differences between the two groups in terms of the proportions of ulcer reduction (0.9503 ± 0.1215 in the LS group vs 0.9192 ± 0.0700 in the LS + ES group, P = 0.169) or ulcer stage (P = 0.446). The prevalence of adverse events related to drugs and bleeding were also similar between the two groups.\nCONCLUSION: Sequential therapy with LS + ES is as effective as LS alone against ESD-induced gastric ulcers."}

{"project":"yaoziqian_800_3","denotations":[{"id":"T1","span":{"begin":38,"end":50},"obj":"CI"},{"id":"T11","span":{"begin":623,"end":625},"obj":"CI"},{"id":"T12","span":{"begin":678,"end":681},"obj":"CI"},{"id":"T13","span":{"begin":682,"end":685},"obj":"CI"},{"id":"T14","span":{"begin":544,"end":560},"obj":"DP"},{"id":"T16","span":{"begin":1222,"end":1224},"obj":"CI"},{"id":"T17","span":{"begin":1257,"end":1260},"obj":"CI"},{"id":"T18","span":{"begin":1261,"end":1264},"obj":"CI"},{"id":"T19","span":{"begin":1452,"end":1455},"obj":"CI"},{"id":"T2","span":{"begin":55,"end":68},"obj":"CI"},{"id":"T20","span":{"begin":1456,"end":1459},"obj":"CI"},{"id":"T21","span":{"begin":1479,"end":1481},"obj":"CI"},{"id":"T23","span":{"begin":564,"end":584},"obj":"DP"},{"id":"T4","span":{"begin":189,"end":202},"obj":"CI"},{"id":"T5","span":{"begin":378,"end":390},"obj":"CI"},{"id":"T6","span":{"begin":392,"end":394},"obj":"CI"},{"id":"T7","span":{"begin":204,"end":206},"obj":"CI"},{"id":"T8","span":{"begin":408,"end":410},"obj":"CI"},{"id":"T24","span":{"begin":416,"end":418},"obj":"CI"},{"id":"T25","span":{"begin":693,"end":695},"obj":"CI"}],"text":"The effect of sequential therapy with lansoprazole and ecabet sodium in treating iatrogenic gastric ulcer after endoscopic submucosal dissection: a randomized prospective study.\nOBJECTIVE: Ecabet sodium (ES) is a new non-systemic anti-ulcer agent belonging to the category of gastroprotective agents. In this study we aimed to compare the efficacy of a combination therapy with lansoprazole (LS) followed by ES with LS alone in treating endoscopic submucosal dissection (ESD)-induced iatrogenic gastric ulcers.\nMETHODS: Patients diagnosed with gastric adenomas or early gastric cancer were randomly divided into either the LS group (30 mg once daily for 4 weeks; n = 45) or the LS + ES group (LS 30 mg once daily for one week followed by ES 1500 mg twice daily for 3 weeks; n = 45). Four weeks after ESD, a follow-up endoscopy was conducted to evaluate the proportions of ulcer reduction and ulcer stages in the two groups.\nRESULTS: In all, 79 patients were included in the final analyses. Both treatment modalities were well-tolerated in most patients, with a drug compliance of over 80%. There were no significant differences between the two groups in terms of the proportions of ulcer reduction (0.9503 ± 0.1215 in the LS group vs 0.9192 ± 0.0700 in the LS + ES group, P = 0.169) or ulcer stage (P = 0.446). The prevalence of adverse events related to drugs and bleeding were also similar between the two groups.\nCONCLUSION: Sequential therapy with LS + ES is as effective as LS alone against ESD-induced gastric ulcers."}